Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

View Full Paper
Ask AI
Bookmark
Share

Authors

OCOnyee ChanDSDavid A. SallmanLPLia Perez

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved overall survival with HCT versus HMA/VEN in elderly AML patients, indicating better treatment strategies.

Key Points

  • To evaluate treatment outcomes of elderly AML patients receiving either HMA/VEN or HCT.
  • Retrospective analysis of 284 elderly AML patients
  • Compared outcomes of HMA/VEN and HCT groups
  • Assessed comorbidity and genetic risk using AML Composite Model and ELN criteria
  • Overall survival at 3 years was 20% for HMA/VEN and 62% for HCT, p<0.001
  • HCT led to significantly better outcomes in patients with adverse genetic risk
  • Relapse rate was lower in HCT group compared to HMA/VEN, p<0.0001

Cite This Study

Chan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d617https://doi.org/10.1182/blood-2025-4300
View Full Paper
Ask AI
Bookmark
Share